| scholarly article | Q13442814 |
| P2093 | author name string | Ghasemi M | |
| Alyasin A | |||
| Mehdinejadiani S | |||
| P2860 | cites work | Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome | Q24234075 |
| Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome | Q24236480 | ||
| Luteal phase support in assisted reproduction cycles | Q24246756 | ||
| GnRH agonist for triggering of final oocyte maturation: time for a change of practice? | Q28308094 | ||
| Neonatal outcome of 937 children born after transfer of cryopreserved embryos obtained by ICSI and IVF and comparison with outcome data of fresh ICSI and IVF cycles | Q31162587 | ||
| GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis | Q33226124 | ||
| The mechanism responsible for the supraphysiologic gonadotropin surge in females treated with gonadotropin-releasing hormone (GnRH) agonist and primed with GnRH antagonist | Q33805486 | ||
| Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience | Q33897147 | ||
| On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: implications for differentiation and implantation | Q34274798 | ||
| Luteal phase support in infertility treatment: a meta-analysis of the randomized trials | Q34803226 | ||
| Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles | Q35019130 | ||
| GnRH agonist vs. hCG for triggering of ovulation--differential effects on gene expression in human granulosa cells | Q35112937 | ||
| Reproductive biology and IVF: ovarian stimulation and luteal phase consequences | Q35162553 | ||
| Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome | Q35623466 | ||
| Luteal phase GnRHa trigger in random start fertility preservation cycles | Q36016200 | ||
| A quantitative assessment of follicle size on oocyte developmental competence | Q36219539 | ||
| GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation | Q36570314 | ||
| Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis | Q36571890 | ||
| Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study | Q37425142 | ||
| An OHSS-Free Clinic by segmentation of IVF treatment | Q37914493 | ||
| Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis | Q38018755 | ||
| GnRH agonist triggering: recent developments | Q38075689 | ||
| Implantation in assisted reproduction: a look at endometrial receptivity | Q38128081 | ||
| Improving the luteal phase after ovarian stimulation: reviewing new options | Q38198300 | ||
| GnRHa trigger for final oocyte maturation: is HCG trigger history? | Q38231926 | ||
| Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases | Q38253309 | ||
| Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. | Q38355567 | ||
| Major drawbacks and additional benefits of agonist trigger--not ovarian hyperstimulation syndrome related | Q38364385 | ||
| Basic understanding of gonadotropin-releasing hormone-agonist triggering | Q38364926 | ||
| Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger | Q38365977 | ||
| Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen–thawed embryo transfer in normal responders | Q38488249 | ||
| Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis | Q38495723 | ||
| Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study | Q39380673 | ||
| FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms | Q40939452 | ||
| Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos | Q41606675 | ||
| Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization | Q42166313 | ||
| Regulation of rat granulosa cell plasminogen activator system: influence of interleukin-1 beta and ovarian follicular development | Q42514045 | ||
| High serum oestradiol concentrations in IVF cycles increase the risk of pregnancy complications related to abnormal placentation | Q42945060 | ||
| Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting | Q43194352 | ||
| Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix | Q43559187 | ||
| Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor | Q44055189 | ||
| Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates | Q44063499 | ||
| Infant and maternal health monitoring using a combined Nordic database on ART and safety | Q44275154 | ||
| Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertil | Q44582470 | ||
| Regulated expression of ADAMTS family members in follicles and cumulus oocyte complexes: evidence for specific and redundant patterns during ovulation | Q45230684 | ||
| GnRHa trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients | Q45411775 | ||
| Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. | Q46021835 | ||
| 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study | Q46129525 | ||
| GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study | Q46370791 | ||
| A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists | Q46568123 | ||
| Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial | Q46913640 | ||
| Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. | Q48622292 | ||
| GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients | Q48623268 | ||
| Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol | Q48653243 | ||
| GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study. | Q48668054 | ||
| Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. | Q48682065 | ||
| Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome | Q48682567 | ||
| A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study | Q48687403 | ||
| Efficacy of induced luteinizing hormone surge after “trigger” with gonadotropin-releasing hormone agonist | Q48687869 | ||
| Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction | Q48735648 | ||
| No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles | Q48747756 | ||
| The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective | Q48794248 | ||
| Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys | Q49047532 | ||
| GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. | Q50641559 | ||
| Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates | Q50643211 | ||
| Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist | Q50798437 | ||
| Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization | Q50801599 | ||
| FSH stimulates hyaluronic acid synthesis by oocyte–cumulus cell complexes from mouse preovulatory follicles | Q59073867 | ||
| Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study | Q59676551 | ||
| Does assisted reproductive treatment increase the risk of birth defects in the offspring? | Q61847447 | ||
| Hormonal dynamics at midcycle: a reevaluation | Q70445378 | ||
| Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy | Q73148530 | ||
| Effect of human chorionic gonadotropin on luteal luteinizing hormone concentrations in natural cycles | Q73932257 | ||
| The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study | Q80747464 | ||
| Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin | Q84058799 | ||
| Pregnancy loss after frozen-embryo transfer--a comparison of three protocols | Q84642594 | ||
| Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol | Q87305772 | ||
| "Triggering" of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF) | Q93746969 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | review article | Q7318358 |
| P304 | page(s) | 557-566 | |
| P577 | publication date | 2016-09-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | International Journal of Reproductive Biomedicine (Yazd, Iran) | Q27727296 |
| P1476 | title | GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article | |
| P478 | volume | 14 |
| Q46778236 | Comparing the effect of gonadotropin-releasing hormone agonist and human chorionic gonadotropin on final oocytes for ovulation triggering among infertile women undergoing intrauterine insemination: An RCT. |
| Q49419476 | Dual trigger of triptorelin and HCG optimizes clinical outcome for high ovarian responder in GnRH-antagonist protocols |
Search more.